Johnson & Johnson (JNJ) FY2025Q4 Earning Prediction
Johnson & Johnson (JNJ) is set to release its FY2025Q4 earnings performance on 01/21 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 24.00B and an earnings per share (EPS) of 2.43 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The earnings forecast predicts a beat driven by strong performance in innovative medicines and MedTech, offsetting legal and market expectation risks.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification:
Fact Data Analysis:
Innovative Medicine Growth: Positive Phase 3 results for Tecvayli (71% reduction in disease progression risk), FDA approval for Rybrevant Faspro (subcutaneous administration improving convenience), and CARVYKTI’s durable remission data (80% of patients progression-free at 2.5 years) demonstrate oncology/immunology strength. These offset STELARA headwinds.
MedTech Momentum: FDA submissions (Ottava Robotic Surgical System) and approvals (TRUFILL for subdural hematoma) validate growth in cardiovascular/surgery segments. RBC Capital notes mid-high single-digit sales growth.
Regulatory Wins: Agreement with the Trump administration exempts JNJ’s pharma products from tariffs, stabilizing margins and avoiding supply disruptions.
Pipeline Catalysts: Lupus drug nipocalimab (Phase 2b success) and manufacturing investments ($55B for U.S. facilities) support long-term revenue.
Analyst Consensus: Barclays, RBC Capital, and Goldman Sachs highlight upside to Q4 estimates, particularly for Darzalex/Tremfya in oncology.
Key Risks:
- Legal settlement ($ 1.5B talc verdict) creates a one-time EPS drag, but operational strength outweighs this.
- Market expectations are elevated (14% stock outperformance vs. S&P 500), requiring a clear beat on core metrics.
Tactical Strategy Recommendations
Trading Strategy:
- Stock: Long JNJ ahead of earnings. High institutional ownership and MedTech/pharma diversification reduce downside risk.
- Options: Buy Jan 2026 $220 calls (delta ~0.6) to capitalize on beat potential. Sell Feb $210 puts for downside protection.
- Rationale: Fact data supports revenue/EPS beats, while tariff exemptions and pipeline wins justify premium valuation.
Earnings Surprise Analysis
JNJ Transcript
The earnings call summary shows strong financial performance, with impressive growth in key products like CARVYKTI and TECVAYLI, and positive MedTech developments. The guidance is optimistic, with increased operational sales and EPS projections. The Q&A reveals confidence in growth strategies and market positioning, despite some uncertainties around litigation and ACA impact. Overall, the positive growth outlook and strategic focus on high-growth areas support a positive sentiment, likely leading to a stock price increase.
JNJ Report
Frequently Asked Questions
What is the Johnson & Johnson FY2025Q4 Earnings Release Date and Time?
Johnson & Johnson (JNJ) is scheduled to release its FY2025Q4 earnings report onJan 21, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Johnson & Johnson FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 24.00B in revenue and an EPS of 2.00 for Johnson & Johnson's FY2025Q4.
What Does Intellectia's AI Predict for Johnson & Johnson FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a Beat forJohnson & Johnson's FY2025Q4 earnings, with a prediction date of Jan 21, 2026. Johnson & Johnson The earnings forecast predicts a beat driven by strong performance in innovative medicines and MedTech, offsetting legal and market expectation risks.
How Can I Use This Earnings Prediction to Trade JNJ Stock?
Leverage Intellectia's AI forecast to position trades ahead of theJan 21, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Johnson & Johnson FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
